Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-24. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
=== Applications === The enhanced sensitivity of eSimoa is crucial for early and accurate biomarker detection in clinical diagnostics, facilitating better disease monitoring and management. In drug discovery, the ability to track subtle changes in enzymatic activity aids in the development of more effective pharmaceuticals by providing detailed insights into enzyme inhibition mechanisms.
== Economic impact == Though the many advances of HPLC and monoliths are highly visible within the confines of the analytical and pharmaceutical industries, it is unlikely that general society is aware of these developments. Currently, consumers may witness technology developments in the analytical sciences industry in the form of a broader array of available pharmaceutical products of higher purity, advanced forensic testing in criminal trials, better environmental monitoring, and faster returns on medical tests. In the future, presumably, this may not be the case. As medicine becomes more individualized over time, consumer awareness that something is improving their quality of care seems more likely. The further thought that monoliths or HPLC are involved is unlikely to concern the general public, however. There are two main cost drivers behind technological change in this industry. Though many different analytical areas use LC, including food and beverage industries, forensics labs, and clinical testing facilities, the largest impetus toward technology developments comes from the research and development and production arms of the pharmaceutical industry. The areas in which high-throughput monolithic column technologies are likely to have the largest economic impact are R&D and downstream processing. From the Research and Development field comes the desire for more resolved, faster separations from smaller sample quantities. The only phase of drug development under direct control of a pharmaceutical company is the R&D stage.
Janis, made by Video Arts Television 4 November A Brush with the Greens, about environmental consumer products; the consumer products company Creightons of Billingshurst was looking at developing new products and had an environmental audit by John Elkington; deep ecology; the PA Consulting Group; the Predicasts database; the CEGB wind energy demonstration site in west Wales at Carmarthen Bay Power Station; a million tonnes of plastic packaging waste was caused in the UK each year; separating plastic waste would allow much more recycling of household plastics; the Greater Manchester Waste Disposal Authority; the Purfleet Board plant in Essex, which itself was powered by landfill gas through a Ruston Gas Turbines TB5000 CHP plant, which closed in 2004; a focus group (four women) takes place, where the product designers sit behind a two-way mirror, with new toothpaste designs placed on a mood board. Narrated by wine critic Jancis Robinson, produced by Mike Cockburn, directed by David Sharp, made by London Scientific Films 11 November Patently Obvious?, about acquiring patents in the UK; scenes from the 1951 The Man in the White Suit and The Dam Busters; Barry Fox of New Scientist, and the invention of FM by Edwin Howard Armstrong; Jeremy Phillips of Queen Mary and Westfield College; computer software cannot be patented; Peter Chilvers, who disputed an American patent; the British Technology Group; Richard Taylor and Paul Kellar of Quantel; in the European Patent Organisation, the UK had 6% of patents but the US and Germany had 25% each; Robert Donat in 1951 The Magic Box.
=== Biomedical applications === Quantitative proteomics has distinct applications in the medical field. Especially in the fields of drug and biomarker discovery. LC-MS/MS techniques have started to over take more traditional methods like the western blot and ELISA due to the cumbersome nature of labeling different and separating proteins using these methods and the more global analysis of protein quantification. Mass spectrometry methods are more sensitive to difference in protein structure like post-translational modification and thus can quantify differing modifications to proteins. Quantitative proteomics can circumvent these issues, only needing sequence information to be performed. It can be applied on a global proteome level, or on specifically isolating binding partners in pull-down or affinity purification experiments. Disadvantages, however, in sensitivity and analysis time must be kept in consideration.
Donald Trump, who was inaugurated as US president in 2017, had repeatedly said during his presidential campaign that he considered China a threat, a stance that heightened speculations of the possibility of a "new cold war with China". Claremont McKenna College professor Minxin Pei said that Trump's election win and "ascent to the presidency" may increase chances of the possibility. In March 2017, a self-declared socialist magazine Monthly Review said, "With the rise of the Trump administration, the new Cold War with Russia has been put on hold", and also said that the Trump administration has planned to shift from Russia to China as its main competitor.
Sources: en.wikipedia.org
In addition to containing the 24-hour ration, the outside of the cardboard box has a range card printed on its side for use by the soldier to record key features and their range from their position. Other variations designed for specific environments exist. The rations are issued with a new folding cooker and fire-lighting fuel called FireDragon made in Wales by BCB International Ltd.
== Safety considerations == Inhalation of crystalline silica harms the lungs, causing silicosis. Amorphous silica is considered to have low toxicity, but prolonged inhalation causes lung changes. Diatomaceous earth is mainly amorphous silica but contains some crystalline silica, especially in the saltwater forms. In a 1978 study of workers, those exposed to natural diatomaceous earth for over five years had no significant lung changes while 40% of those exposed to the calcined form had developed pneumoconiosis. Today's standard diatomaceous earth formulations are safer to use, as they are predominantly made of amorphous silica and contain little or no crystalline silica. The crystalline silica content of diatomaceous earth is regulated in the United States by the Occupational Safety and Health Administration (OSHA). There are guidelines from the National Institute for Occupational Safety and Health that set maximum amounts allowable in the product (1%) and in the air near the breathing zone of workers, with a recommended exposure limit at 6 mg/m3 over an 8-hour workday. OSHA has set a permissible exposure limit for diatomaceous earth as 20 mppcf (80 mg/m3/%SiO2). At levels of 3,000 mg/m3, diatomaceous earth is immediately dangerous to life and health. In the 1930s, workers with long-term occupational exposure in the cristobalite diatomaceous earth industry who were exposed to high levels of airborne crystalline silica over decades were found to have an increased risk of silicosis.
The long passage up the heavily tidal Avon Gorge, which had made the port highly secure during the Middle Ages, had become a liability which the construction of a new "Floating Harbour" (designed by William Jessop) in 1804–1809 failed to overcome. Nevertheless, Bristol's population (61,000 in 1801) grew fivefold during the 19th century, supported by growing commerce. It was particularly associated with the leading engineer Isambard Kingdom Brunel, who designed the Great Western Railway between Bristol and London, two pioneering Bristol-built steamships, the SS Great Western and the SS Great Britain, and the Clifton Suspension Bridge.
The chain catshark or chain dogfish (Scyliorhinus retifer) is a small, reticulated catshark that is biofluorescent. The species is common in the Northwest Atlantic, Gulf of Mexico, and Caribbean. It is harmless and rarely encountered by humans. It has very similar reproductive traits to the small-spotted catshark (S. canicula).
Sources: en.wikipedia.org
The word metagenics uses the prefix meta and the suffix gen. Literally, it means "the creation of something which creates". In the context of biotechnology, metagenics is the practice of engineering organisms to create a specific enzyme, protein, or other biochemical from simpler starting materials. The genetic engineering of E. coli with the specific task of producing human insulin from starting amino acids is an example. E. coli has also been engineered to digest plant biomass and use it to produce hydrocarbons in order to synthesize biofuels. The applications of metagenics on E. coli also include higher alcohols, fatty-acid based chemicals and terpenes.
== Traditions == To commemorate the 1944 Waal assault river crossing made by the 504th Parachute Infantry Regiment and the 307th Engineer Battalion (Airborne) during Operation Market Garden, an annual Crossing of the Waal competition is staged on the anniversary of the operation at McKellar's Lake near Fort Bragg. The winning company receives a paddle.
=== Singapore === The TCM Practitioners Act was passed by Parliament in 2000 and the TCM Practitioners Board was established in 2001 as a statutory board under the Ministry of Health, to register and regulate TCM practitioners. The requirements for registration include possession of a diploma or degree from a TCM educational institution/university on a gazetted list, either structured TCM clinical training at an approved local TCM educational institution or foreign TCM registration together with supervised TCM clinical attachment/practice at an approved local TCM clinic, and upon meeting these requirements, passing the Singapore TCM Physicians Registration Examination (STRE) conducted by the TCM Practitioners Board. In 2024, Nanyang Technological University will offer the four-year Bachelor of Chinese Medicine programme, which is the first local programme accredited by the Ministry of Health.
=== Funerary terraces === Two funerary enclosures were discovered north of the voie d'Italie. The northernmost one was destroyed in 1973 to make way for the Centre Bourse. Each rectangular enclosure has an area of approximately 100 m2 (1,100 sq ft). They were in fact terraces intended to be seen from the voie d'Italie. The preserved enclosure is decorated with alternating metopes and triglyphs which rest on a plinth. In the center of this terrace a square-shaped plinth was discovered carved from large white limestone: it might have been the base of an altar or statue. The enclosures were built at the beginning of the 4th century BC. The excavations have revealed several cremations carried out in situ — nineteen in the northern enclosure and six next to the monument with triglyphs. The remains were recovered; they were found in lead, ceramic or bronze urns, which were then placed within stone boxes and arranged in a pit of funerary terraces. Some of these urns are exhibited at the Marseille History Museum. All the tombs date back to the 4th century BC, except for one cremation which might have occurred in the 3rd century BC. At the beginning of the 2nd century, the use of these funerary terraces was abandoned completely and the site covered up with earth.
Acrokeratoelastoidosis of Costa (keratoelastoidosis marginalis) Aquagenic keratoderma (acquired aquagenic palmoplantar keratoderma, aquagenic syringeal acrokeratoderma, aquagenic wrinkling of the palms, transient reactive papulotranslucent acrokeratoderma) Bart–Pumphrey syndrome (palmoplantar keratoderma with knuckle pads and leukonychia and deafness) Camisa disease Carvajal syndrome (striate palmoplantar keratoderma with woolly hair and cardiomyopathy, striate palmoplantar keratoderma with woolly hair and left ventricular dilated cardiomyopathy) Corneodermatoosseous syndrome (CDO syndrome) Diffuse epidermolytic palmoplantar keratoderma (palmoplantar keratoderma cum degeneratione granulosa Vörner, Vörner's epidermolytic palmoplantar keratoderma, Vörner keratoderma) Diffuse nonepidermolytic palmoplantar keratoderma (diffuse orthohyperkeratotic keratoderma, hereditary palmoplantar keratoderma, keratosis extremitatum progrediens, keratosis palmoplantaris diffusa circumscripta, tylosis, Unna–Thost disease, Unna–Thost keratoderma) Erythrokeratodermia variabilis (erythrokeratodermia figurata variabilis, keratosis extremitatum progrediens, keratosis palmoplantaris transgrediens et progrediens, Mendes da Costa syndrome, Mendes da Costa type erythrokeratodermia, progressive symmetric erythrokeratoderma) Focal acral hyperkeratosis (acrokeratoelastoidosis lichenoides, degenerative collagenous plaques of the hand) Focal palmoplantar and gingival keratosis Focal palmoplantar keratoderma with oral mucosal hyperkeratosis (focal epidermolytic palmoplantar keratoderma, hereditary painful callosities, hereditary painful callosity syndrome, keratosis follicularis, keratosis palmoplantaris nummularis, nummular epidermolytic palmoplantar keratoderma) Haim–Munk syndrome (palmoplantar keratoderma with periodontitis and arachnodactyly and acro-osteolysis) Hidrotic ectodermal dysplasia (alopecia congenita with keratosis palmoplantaris, Clouston syndrome, Clouston's hidrotic ectodermal dysplasia, Fischer–Jacobsen–Clouston syndrome, keratosis palmaris with drumstick fingers, palmoplantar keratoderma and clubbing) Howel–Evans syndrome (familial keratoderma with carcinoma of the esophagus, focal non-epidermolytic palmoplantar keratoderma with carcinoma of the esophagus, palmoplantar ectodermal dysplasia type III, palmoplantar keratoderma associated with esophageal cancer, tylosis, tylosis–esophageal carcinoma) Hystrix-like ichthyosis–deafness syndrome (HID syndrome) Keratoderma climactericum (acquired plantar keratoderma, climacteric keratoderma, Haxthausen's disease) Keratosis punctata palmaris et plantaris (Buschke–Fischer–Brauer disease, Davis Colley disease, keratoderma disseminatum palmaris et plantaris, keratosis papulosa, keratoderma punctatum, keratodermia punctata, keratoma hereditarium dissipatum palmare et plantare, palmar and plantar seed dermatoses, palmar keratoses, papulotranslucent acrokeratoderma, punctate keratoderma, punctate keratoses of the palms and soles, maculosa disseminata) Keratitis–ichthyosis–deafness syndrome (erythrokeratodermia progressiva Burns, ichthyosiform erythroderma with corneal involvement and deafness, KID syndrome) Mal de Meleda (acral keratoderma, Gamborg–Nielsen keratoderma, mutilating palmoplantar keratoderma of the Gamborg–Nielsen type, palmoplantar ectodermal dysplasia type VIII, palmoplantar keratoderma of the Norrbotten type) Naxos syndrome (diffuse non-epidermolytic palmoplantar keratoderma with woolly hair and cardiomyopathy, diffuse palmoplantar keratoderma with woolly hair and arrythmogenic right ventricular cardiomyopathy of Naxos, Naxos disease) Olmsted syndrome (mutilating palmoplantar keratoderma with periorificial keratotic plaques, mutilating palmoplantar keratoderma with periorificial plaques, polykeratosis of Touraine) Pachyonychia congenita type I (Jadassohn–Lewandowsky syndrome) Pachyonychia congenita type II (Jackson–Lawler pachyonychia congenita, Jackson–Sertoli syndrome) Palmoplantar keratoderma and spastic paraplegia (Charcot–Marie–Tooth disease with palmoplantar keratoderma and nail dystrophy) Palmoplantar keratoderma of Sybert (Greither palmoplantar keratoderma, Greither syndrome, keratosis extremitatum hereditaria progrediens, keratosis palmoplantaris transgrediens et progrediens, Sybert keratoderma, transgrediens and progrediens palmoplantar keratoderma) Papillon–Lefèvre syndrome (palmoplantar keratoderma with periodontitis) Porokeratosis plantaris discreta Punctate palmoplantar keratoderma Schöpf–Schulz–Passarge syndrome (eyelid cysts with palmoplantar keratoderma and hypodontia and hypotrichosis) Scleroatrophic syndrome of Huriez (Huriez syndrome, palmoplantar keratoderma with scleroatrophy, palmoplantar keratoderma with sclerodactyly, scleroatrophic and keratotic dermatosis of the limbs, sclerotylosis) Striate palmoplantar keratoderma (acral keratoderma, Brünauer–Fuhs–Siemens type of palmoplantar keratoderma, focal non-epidermolytic palmoplantar keratoderma, keratosis palmoplantaris varians, palmoplantar keratoderma areata, palmoplantar keratoderma striata, Wachter keratoderma, Wachters palmoplantar keratoderma) Spiny keratoderma (porokeratosis punctata palmaris et plantaris, punctate keratoderma, punctate porokeratosis of the palms and soles) Tyrosinemia type II (oculocutaneous tyrosinemia, Richner–Hanhart syndrome) Vohwinkel syndrome (keratoderma hereditaria mutilans, keratoma hereditaria mutilans, mutilating keratoderma of Vohwinkel, mutilating palmoplantar keratoderma)
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.